The three goals of the Cancer Therapeutic Program are: 1) to enhance and facilitate programmatic and interprogrammatic interaction and collaboration between basic scientists and clinical investigators in cancer therapeutics;2) to promote the discovery, development, and application of novel therapeutic approaches;and 3) to develop translational and laboratory-based clinical investigations of new therapeutic agents and new therapeutic approaches. These goals are achieved through three Research Themes. Theme 1 is focused on technology development for target identification and drug discovery, with the goal of applying these new technologies (such as combinatorial chemistry, medicinal chemistry, computational biology, structural biology, nanotechnology, and high-throughput assays) to specific drug development projects in theme 2. For example, in theme 2, we are developing: cancer cell surface targeting ligands, novel targeting nanocarriers for cancer drug delivery and imaging, tyrosine kinase inhibitors, and nanoparticles for cancer vaccine and immunotherapy. In Theme 3, we use a collaborative group of molecular biologists, translational scientists, pharmacologists, and clinical investigators to facilitate the design and conduct of laboratory-driven clinical investigations. In view of the preclinical expertise in drug discovery and drug development available within the Program, there is great potential to translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies. One example of such translation is the development of novel nanoformulations of paclitaxel soon to be tested in human. Furthermore, the expertise represented within this group of investigators provides a conduit for acquisition of new therapeutic agents from the NCI or industry. Providing a platform for clinical trials are specific project areas in clinical investigation and translational studies, including drug development awards (N01, U01, U10) and investigator-initiated trials. The program has 46 members from 13 different departments at UC Davis and 1 department at LLNL. It has 25 NCl-funded projects for $3.9 million ADC (total peer-reviewed funding, $8.8 million ADC). Of the 728 publications for the last funding period, 44% are inter-programmatic and 29% are intra-programmatic.

Public Health Relevance

Through the three interactive research themes, investigators from the Cancer Therapeutic Program will translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
United States
Zip Code
Zeng, Shu-Xiong; Zhu, Yanjun; Ma, Ai-Hong et al. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res 23:6580-6591
Zhong, Cheng; Han, Ju; Borowsky, Alexander et al. (2017) When machine vision meets histology: A comparative evaluation of model architecture for classification of histology sections. Med Image Anal 35:530-543
Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32
Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67
York, D; Sproul, C D; Chikere, N et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol :
Yap, Stanley A; Yuh, Lindsay M; Evans, Christopher P et al. (2017) Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol 35:277-283
(2017) New and emerging developments in extensive-stage small cell lung cancer therapeutics: Erratum. Curr Opin Oncol 29:88
Johnson, Lianna M; Du, Jiamu; Hale, Christopher J et al. (2017) Corrigendum: SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature 543:136
Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755
Wan, Debin; Yang, Jun; Barnych, Bogdan et al. (2017) A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine. J Lipid Res 58:798-808

Showing the most recent 10 out of 733 publications